Total Debt for Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's latest reported total debt is $2.71B USD. Total debt is the sum of short-term and long-term interest-bearing borrowings on the balance sheet (notes, bonds, term loans, lease liabilities). Useful for leverage and refinancing risk — combine with cash on hand for net debt, and see total liabilities for the broader obligations picture.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingTotal DebtSwitch metric
Latest period
$2.71B
YoY change
+0.1%
5Y CAGR
+0.1%
Peak year (2025)
$2.71B
Latest annual
$2.71B
Total Debt history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Total Debt history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| Fiscal year | Period ended | Reported | Total Debt | YoY |
|---|---|---|---|---|
| 2025 | $2.71B | +0.1% | ||
| 2024 | $2.70B | +0.1% | ||
| 2023 | $2.70B | +0.1% | ||
| 2022 | $2.70B | +0.1% | ||
| 2021 | $2.70B | +0.1% | ||
| 2020 | $2.70B | +277.6% | ||
| 2019 | $713.90M | +0.8% | ||
| 2018 | $708.50M | +0.7% | ||
| 2017 | $703.45M | +46.2% | ||
| 2016 | $481.13M | +28.1% | ||
| 2015 | $375.51M | -18.2% | ||
| 2014 | $459.06M | -9.2% | ||
| 2013 | $505.51M | +10.5% | ||
| 2012 | $457.33M | +5.0% | ||
| 2011 | $435.53M | +172.2% | ||
| 2010 | $160.03M | +46.8% | ||
| 2009 | $109.02M | +2040.6% | ||
| 2008 | $5.09M | -97.5% | ||
| 2007 | $202.29M | +1.1% | ||
| 2006 | $200.00M | 0.0% | ||
| 2005 | $200.00M | 0.0% | ||
| 2004 | $200.00M | -6.5% | ||
| 2003 | $213.82M | +6.8% | ||
| 2002 | $200.15M | -0.2% | ||
| 2001 | $200.58M | +7381.4% | ||
| 2000 | $2.68M | -34.6% | ||
| 1999 | $4.10M | -2.4% | ||
| 1998 | $4.20M | -25.0% | ||
| 1997 | $5.60M | -35.6% | ||
| 1996 | $8.70M | -8.4% | ||
| 1995 | $9.50M | -22.8% | ||
| 1994 | $12.30M | +64.0% | ||
| 1993 | $7.50M | +10.3% | ||
| 1992 | $6.80M | +142.9% | ||
| 1991 | $2.80M | — | ||
| 1990 | $0 | — |
Total Debt values are taken from Regeneron Pharmaceuticals's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Regeneron Pharmaceuticals (REGN) reported total debt of $2.71B – edged up 0.1% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Regeneron Pharmaceuticals total debt compounded at +0.1% per year, with the latest reading among the more recent periods of the dataset.
Across the available history, total debt reached its high of $2.71B in 2025 and its low of $0 in 1990.
Regeneron Pharmaceuticals (REGN) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $52.57B.
Regeneron Pharmaceuticals Total Debt by Year
Regeneron Pharmaceuticals Total Debt 2025: $2.71B
Regeneron Pharmaceuticals total debt in 2025 was $2.71B, edged up 0.1% from 2024. This figure represents the highest annual value in the available history.
Regeneron Pharmaceuticals Total Debt 2024: $2.70B
Regeneron Pharmaceuticals total debt in 2024 was $2.70B, edged up 0.1% from 2023.
Regeneron Pharmaceuticals Total Debt 2023: $2.70B
Regeneron Pharmaceuticals total debt in 2023 was $2.70B, edged up 0.1% from 2022.
Regeneron Pharmaceuticals Total Debt 2022: $2.70B
Regeneron Pharmaceuticals total debt in 2022 was $2.70B, edged up 0.1% from 2021.
Regeneron Pharmaceuticals Total Debt 2021: $2.70B
Regeneron Pharmaceuticals total debt in 2021 was $2.70B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — Total Debt
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest total debt.
| Company | Total Debt | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $130.96B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $78.39B | Healthcare |
| AbbVie Inc. (ABBV) | $69.07B | Healthcare |
| Amgen Inc. (AMGN) | $54.60B | Healthcare |
| Merck & Co., Inc. (MRK) | $50.53B | Healthcare |
| Johnson & Johnson (JNJ) | $47.93B | Healthcare |
| Eli Lilly and Company (LLY) | $42.50B | Healthcare |
| AstraZeneca PLC (AZN) | $29.70B | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's total debt?
- Latest reported total debt for Regeneron Pharmaceuticals (REGN) is $2.71B (period ending December 31, 2025).
How has Regeneron Pharmaceuticals total debt changed year-over-year?
- Regeneron Pharmaceuticals (REGN) total debt changed +0.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals total debt?
- Regeneron Pharmaceuticals (REGN) total debt compound annual growth rate is +0.1% over the most recent 5 years available.
When did Regeneron Pharmaceuticals total debt hit its highest annual value?
- Regeneron Pharmaceuticals total debt reached its highest annual value of $2.71B in 2025.
What was Regeneron Pharmaceuticals total debt in 2024?
- Regeneron Pharmaceuticals (REGN) total debt in 2024 was $2.70B.
What was Regeneron Pharmaceuticals total debt in 2025?
- Regeneron Pharmaceuticals (REGN) total debt in 2025 was $2.71B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.